Hepatitis B Virus (HBV)

New insights into the role of nitric oxide in cardiovascular protection (part 8)

 As shown in Figure 2A, neither the PDE2 inhibitor nor the PDE4 inhibitor alone increased cAMP level, regardless of presence or absence of nitric oxide-cGMP pathway modulators. However, the combination of both inhibitors potently increased cAMP levels (eight- to 13-fold compared with drug vehicle). In the same samples, no significant effects of PDE2 and PDE4 inhibitors (alone or in combination) were observed on cGMP contents in control and L-NAME treated cells. Surprisingly, in the presence of the nitric oxide synthase substrate, cGMP content was increased significantly by the PDE4 inhibitor. Combination of PDE2 and PDE4 inhibitors resulted in a marked increase in cGMP level (to 153%, Figure 2B). None of these effects was observed when the nitric oxide synthase inhibitor was added with the nitric oxide synthase substrate.New insights into the role of nitric oxide in cardiovascular protection Shop online with the best pharmacy that will ensure high quality of your medications and will offer cheapest Generic Allegra with no rx required any time you need this or any other one for your medical problem.

Figure 2 Effects of phosphodiesterase inhibitors on (A) cAMP and (B) cGMP levels in cultured bovine aortic endothelial cells exposed to L-arginine. Cells were incubatedfor 5 mins with drug vehicle (D), 50^M cilostamide (C), 20^M rolipram (R)or50^M cilostamideplus 20^M rolipram (C+R). Results are expressed as mean ±SEM of triplicate determinations from three different cultures. *P<0.05 and ***P<0.001 compared with drug vehicle condition in the same treatment. +P<0.05 effect of C+R compared with effect ofcilostamide. Data taken from reference 14, with permission 

Category: Cardiovascular protection

Tags: Cardiovascular protection, Cyclic nucleotides, Endothelium, Myocardium, Nitric oxide, Vascular smooth muscle

Leave a Reply

Your email address will not be published. Required fields are marked *